SCHEMBL23055771

SCHEMBL23055771

CN1CCc2c(-c3cnn(C)c3)cccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 4/20 0.45
▸ BRD4 O60885 2/20 0.42
▸ GRM1 Q13255 2/20 0.42
▸ PDK2 Q15119 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ S1PR3 Q99500 1/20 0.41
▸ SMARCA2 P51531 1/20 0.40
▸ SMARCA4 P51532 1/20 0.40
▸ CHRM1 P11229 2/20 0.40
▸ LCK P06239 1/20 0.40
▸ BTK Q06187 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ CREBBP Q92793 2/20 0.39
▸ ADRA2A P08913 1/20 0.37
▸ ADRA1A P35348 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ INCENP Q9NQS7 1/20 0.37
▸ TPX2 Q9ULW0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809615 0.81 BRD4 (0.38) GRM5BRD4GRM1SMARCA2SMARCA4
SCHEMBL17809602 0.79 BRD4 (0.41) BRD4PDK2CREBBPAURKAAURKB
SCHEMBL2625808 0.79 HTR2C (0.47) S1PR1S1PR3
SCHEMBL25124593 0.79 S1PR1 (0.43) S1PR1S1PR3
SCHEMBL23639223 0.78 UCHL1 (0.46) GRM5GRM1S1PR1S1PR3
SCHEMBL23055375 0.78 UCHL1 (0.50) GRM5GRM1S1PR1S1PR3
SCHEMBL25124392 0.78 UCHL1 (0.50) GRM5ADRA2AADRA1A
SCHEMBL24783932 0.77 UCHL1 (0.50) PDK2S1PR1S1PR3ADRA1A
SCHEMBL17809532 0.76 GRM5 (0.39) GRM5BRD4GRM1PDK2SMARCA2
SCHEMBL24783739 0.75 S1PR1 (0.43) S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 — — US disclosed
EP-4104861-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2022-12-21 — — EP disclosed
WO-2021039961-A1 RING-FUSED PYRAZOLE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 GRM5 421/4885BRD4 1846/4885GRM1 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback